The US would be very costly to list and a double whammy of compliance, although we have the cash to do it, I think staying on the ASX is a better play for now until we at least grow enough to warrant a dual list. Revenues cranking in, deals being done and some solid metrics would make for a much larger listing and raise a lot more capital at higher prices if we are patient enough. $100m revenue would make us an easy 10 figure business there.
Ann: Botanix $40 Million Capital Raising for Sofdra Rollout, page-212
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.025(8.62%) |
Mkt cap ! $617.6M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 32.5¢ | 29.5¢ | $3.568M | 11.49M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 8133 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 45000 | 1 |
View Market Depth
| Last trade - 15.59pm 26/06/2025 (20 minute delay) ? |
| BOT (ASX) Chart |